Elderly patients with metastatic renal cell carcinoma: Position paper from the International Society of Geriatric Oncology Journal Article
| Authors: | Kanesvaran, R.; Le Saux, O.; Motzer, R.; Choueiri, T. K.; Scotté, F.; Bellmunt, J.; Launay-Vacher, V. |
| Article Title: | Elderly patients with metastatic renal cell carcinoma: Position paper from the International Society of Geriatric Oncology |
| Abstract: | Therapy for metastatic renal cell carcinoma should be tailored to the circumstances and preferences of the individual patient. Age should not be a barrier to effective treatment. Systematic geriatric screening and assessment contributes to the goal of personalised management, in addition to the involvement of a multidisciplinary team. A task force from the International Society of Geriatric Oncology (SIOG) updated its 2009 consensus statement on the management of elderly patients with metastatic renal cell carcinoma by reviewing data from studies involving recently approved targeted drugs and immunotherapies for this disease. Overall, it seems that age alone does not appreciably affect efficacy. Among the pivotal studies that were included, there is a striking scarcity of analyses that relate toxic effects to patient age. Even if the adverse effects of therapy are no more frequent or severe in elderly patients than in their younger counterparts, the practical, psychological, and functional impact of treatment may be greater, especially if toxic effects are chronic and cumulative. © 2018 Elsevier Ltd |
| Keywords: | overall survival; drug tolerability; fatigue; review; sorafenib; bevacizumab; placebo; sunitinib; drug efficacy; drug safety; alpha interferon; drug megadose; cancer incidence; interleukin 2; cancer immunotherapy; progression free survival; quality of life; anemia; thrombocytopenia; practice guideline; oncology; temsirolimus; comorbidity; pazopanib; drug monitoring; axitinib; elderly care; kidney metastasis; geriatric patient; everolimus; drug indication; intermediate risk patient; decreased appetite; low risk patient; frailty; cancer prognosis; medication compliance; cabozantinib; nivolumab; lenvatinib; human; priority journal |
| Journal Title: | Lancet Oncology |
| Volume: | 19 |
| Issue: | 6 |
| ISSN: | 1470-2045 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2018-06-01 |
| Start Page: | e317 |
| End Page: | e326 |
| Language: | English |
| DOI: | 10.1016/s1470-2045(18)30125-6 |
| PROVIDER: | scopus |
| PUBMED: | 29893263 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 2 July 2018 -- Source: Scopus |
